Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
For immediate release 30th May 2017 SCIENCE IN SPORT PLC ("SiS" or the "Company") SIS granted patent for novel WHEY20 Science in Sport plc (AIM: SIS), a leading sports nutrition company that develops, manufactures and markets sports nutrition products for professional athletes and sports enthusiasts, is pleased to announce it has received a Certificate of Grant of Patent for WHEY20 reflecting the unique features and benefits of the product. SiS launched its novel WHEY20 protein gel ('WHEY20') in January 2016, which helps athletes' maintain muscle mass and can also promote muscle growth. Sales of WHEY20 have been ahead of forecast in the first year and this year sees a relaunch with two new flavours. The production of WHEY20 required several technical challenges to be overcome and marks a significant breakthrough in the creation of a ready-to consume high-quality protein. WHEY20's unique composition provides consumers with a portable, highly concentrated source of whey protein (20g) that does not require refrigeration. These unique features give WHEY20 widespread appeal in the sports and health and gym markets. Whey protein is central to the WHEY20 formulation as this protein is rich in essential amino acids, especially the branched chain amino acids (BCAAs). The composition of whey protein is almost identical to muscle tissue, this makes it the ideal protein source for athletes who wish to maintain muscle tissue, or increase muscle mass . Several gels on the market contain collagen. This has a very different amino acid content to human muscle and is nutritionally inferior to whey protein. Most existing whey protein products on the market are powders, which have to be mixed by the consumer. Some ready to drink products provide a convenient source of whey protein, but often require refrigeration and invariably they have a lower whey protein content than WHEY20. SiS Chief Executive Stephen Moon commented: "Science and innovation underpins everything we do and we are delighted to continue to be at the cutting edge of developments in sports science and the manufacturing process of products, whilst building a portfolio of patents. We have a very strong innovation pipeline for 2017 onwards, continuing to work on further innovation to fuel professional athletes and sports enthusiasts." For further information: Science in Sport PLC
Provexis PLC Trading Update RNS Number : 6959E Provexis PLC 10 May 2017 10 May 2017 Provexis plc Trading update Provexis plc ('Provexis' or the 'Company'), the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, is pleased to provide an update on trading following the end of its financial year on 31 March 2017. In its preliminary results statement currently scheduled for early September the Company expects to report on a strong year of progress. The Company's Alliance partner DSM Nutritional Products has continued to develop the market actively for Fruitflow® in all global markets. More than 50 regional consumer healthcare brands have now been launched by direct customers of DSM, and a number of further regional brands have been launched through DSM's distributor channels. The Company expects to report revenues for the year ended 31 March 2017 of £228k, a 148% year on year increase (2016: £92k). Revenues accruing to the Company for the year from its profit sharing Alliance for Fruitflow® were £153k, a 66% year on year increase (2016: £92k). The Company launched its Fruitflow® + Omega-3 dietary supplement product in late June 2016 and in its nine months on sale the product achieved sales of £29k for the financial year to 31 March 2017 through the new e-commerce website www.fruitflowplus.com. The balance of revenue recognised in the period reflects amounts of £46k (2016: £Nil) received for marketing support; the related marketing expenditure is included as part of administrative costs. The Company expects to report an underlying operating loss for the year of £382k (2016: loss of £385k), a record low for the Group. An increasing number of further commercial projects have been initiated by DSM with prospective customers, including some prospective customers which are part of global businesses, with good prospects for these projects to be launched as consumer products. The Company and DSM have seen an encouraging increase in brand awareness and customer interest in Fruitflow® in recent months, and the total projected annual sales value of the prospective sales pipeline for Fruitflow® has continued to increase, now standing at an all-time high level. MOU for a research and development collaboration with By-Health Co., Ltd for Fruitflow® In April 2017 the Company announced that it had entered into a memorandum of understanding with BY-HEALTH Co., Ltd, a substantial listed Chinese dietary supplement business, which is intended to result in a research and collaboration agreement with BY-HEALTH for Fruitflow®. The Company also confirmed separately that Provexis and DSM were working with BY-HEALTH to support the planned launch of some Fruitflow® based products in the Chinese mark
Provexis PLC Results of Placing RNS Number : 6957E Provexis PLC 10 May 2017 10 May 2017 Provexis plc Results of placing Provexis plc ('Provexis' or the 'Company'), the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, is pleased to announce it has raised a gross £350,000 via a placing (the "Placing"), conditional on admission to trading on AIM, of 70,000,000 new ordinary shares of 0.1p each (the "New Provexis Shares") with new and existing investors. The New Provexis Shares have been issued at a gross 0.50p per share, and rank pari passu in all respects with the existing ordinary shares of 0.1p each in Provexis. No commissions or expenses will be payable on the issue of the New Provexis Shares. The Placing represents a gross discount of 16.7 per cent to the closing mid-market price per Ordinary Share on 9 May 2017, being the latest practicable date prior to this announcement. The Company's RNS announcement of 2 May 2017 confirmed that the Company was in late stage discussions with a small group of investors in relation to two subscriptions to raise further working capital for the Company, and the placing announced today completes the First Subscription. The Company's announcement of 2 May 2017 stated that the company then had legally binding commitments in the First Subscription to raise £170,000 at a subscription price of 0.50 pence per ordinary share, and non-legally binding indications of interest in the First Subscription to raise approximately a further £30,000 at 0.50 pence per ordinary share. The £350,000 Placing announced today therefore represents a £150,000 increase over the £200,000 total interest from investors announced on 2 May. The Company will receive the full £350,000 proceeds raised from the Placing announced today, which will be used to provide the Company with additional working capital to support its growth plans over the coming years, to include the research and collaboration agreement announced in April 2017 with BY-HEALTH for Fruitflow®. Application will be made to the London Stock Exchange for the 70,000,000 New Provexis Shares to be admitted to trading on AIM. It is expected that the admission will become effective and that trading in the New Provexis Shares will commence on 16 May 2017 ("Admission"). Following Admission, the Company's enlarged issued share capital will comprise 1,820,818,174 ordinary shares with voting rights. The Company does not hold any shares in treasury. This figure of 1,820,818,174 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transpa
Provexis PLC Funding Update RNS Number : 8472D Provexis PLC 02 May 2017 2 May 2017 Provexis plc Funding Update Provexis plc ('Provexis' or the 'Company'), the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, is pleased to announce a funding update. The funding update follows guidance from the Company in its interim results, released on 30 December 2016, that the business would need to raise further equity finance in the first four months of 2017. The Company today announces that it is in late stage discussions with a small group of investors in relation to two subscriptions to raise further working capital for the Company. First Subscription - completion expected in May 2017 The Directors currently have legally binding commitments in the First Subscription to raise £170,000 at a subscription price of 0.50 pence per ordinary share, and non-legally binding indications of interest in the First Subscription to raise approximately a further £30,000 at 0.50 pence per ordinary share. No commissions or expenses will be payable on the First Subscription. A further announcement concerning the First Subscription will be made by the Company on or before Wednesday 10 May 2017. Second Subscription - completion expected in June 2017 The Company has applied to Her Majesty's Revenue and Customs ('HMRC') for advance assurance that it would be eligible to issue new ordinary shares under HMRC's Enterprise Investment Scheme ('EIS'). The Company is listed on the Alternative Investment Market ('AIM') which is not considered by HMRC to be to be a 'recognised exchange' under the EIS rules, which means that AIM listed companies can raise money under EIS if they satisfy all the necessary conditions. The Company has received positive EIS advance assurance clearance from HMRC on a number of previous occasions, most recently in July 2012, and it has previously issued shares under EIS. However, the EIS eligibility rules for companies and investors have undergone a number of changes in recent years hence the need to submit a new advance assurance application, as requested by a number of prospective investors in the planned Second Subscription. The Directors currently have non-legally binding indications of interest in the Second Subscription to raise approximately £370,000 at a subscription price of 0.50 pence per ordinary share with no commissions or expenses payable, of which approximately £250,000 is likely to be subject to the Company receiving positive EIS advance assurance clearance from HMRC. The process of obtaining full EIS advance assurance clearance from HMRC is likely to take some weeks, and the outcome from this process is currently uncertain given recent changes to the EIS eligibility rules for companies and investors. A further announcement concerning EIS and the rela
ReNeuron Group plc Update on progress in ophthalmology programmes RNS Number : 9273C ReNeuron Group plc 21 April 2017 AIM: RENE 21 April 2017 ReNeuron Group plc ReNeuron successfully develops cryopreserved formulation of its retinal stem cell therapy candidate and expands ophthalmology programmes ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on its cell therapy development programmes targeting degenerative diseases of the retina. We are pleased to report that we have successfully developed a cryopreserved formulation of our human retinal progenitor cell (hRPC) therapeutic candidate. The ability to cryopreserve our retinal cell therapy candidate at drug product level represents a major step forward for our retinal disease programme and mirrors the earlier breakthrough we achieved with the cryopreservation of our CTX cell therapy candidate. This new hRPC formulation enables the cells to be frozen for shipping and storage and easily thawed at the point of clinical use. This freeze-thaw modality enables a greatly enhanced shelf life for the product, lower prospective cost of goods and the capability to ship the cells for clinical and commercial application anywhere on the globe. As a result of the above development, we will shortly file an application to the FDA seeking approval to switch from the fresh hRPC formulation to the new cryopreserved formulation for dosing of the third and final Phase I dose cohort of our ongoing US Phase I/II clinical trial in retinitis pigmentosa (RP) patients. This study, which is being conducted at Massachusetts Eye and Ear Infirmary in Boston, is an open-label, dose escalation study to evaluate the safety, tolerability and preliminary efficacy of our hRPC stem cell therapy candidate in patients with advanced RP. The new hRPC formulation has also allowed an expansion of ReNeuron's clinical programmes in ophthalmology. Firstly, subject to regulatory approval, we intend to expand the Phase II element of the ongoing Phase I/II clinical trial in RP from six to 20 patients in order to provide a richer data set from which to embark on a subsequent Phase II/III pivotal study. In order to maintain patient recruitment pace and reduce reliance on a single clinical site, we also intend to open up further US clinical sites to this study. As a consequence of these changes, we expect safety and tolerability data from the Phase I part of the RP study in the first nine patients later this year, with longer term safety data as well as efficacy read-outs from the enlarged Phase II part of the study in the second half of 2018. Secondly, we intend to expand our hRPC retinal disease programmes into a further disease indication, cone-rod dystrophy (CRD). In contrast to RP, where the initial impact is a loss of rods leading to a deterioration in peripher
ReNeuron Group plc Update on clinical strategy in stroke disability RNS Number : 9274C ReNeuron Group plc 21 April 2017 AIM: RENE 21 April 2017 ReNeuron Group plc ReNeuron advances global clinical development strategy with cell therapy candidate for stroke disability ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on its CTX-based cell therapy development programmes. In December 2016, we announced positive data from the Phase II clinical trial (PISCES II) of our CTX cell therapy candidate for stroke disability. PISCES II is a single arm, open-label study in patients living with disability resulting from ischaemic stroke. As a result of the positive data from this study, we are pursuing our plans to commence a randomised, placebo-controlled, Phase III clinical trial in the USA and Europe in patients who are living with disability post-stroke. As part of these preparations, we are conducting an End of Phase II meeting with the FDA later this month in order to seek further regulatory guidance prior to our submitting a formal application ("IND") to commence the US arm of the Phase III study. Subject to the feedback from this meeting, we plan to file the IND later this quarter with the aim of commencing the Phase III study in the second half of this year. Separately, we have consulted with the European Medicines Agency on our plans for the Phase III stroke study. We have taken the advice received into account when developing our protocol for the study. In this regard, we intend to file a clinical trial application to regulatory authorities in Europe, shortly after the corresponding US submission. Meetings with the Japanese regulatory agency ("PDMA") are also ongoing in order to advance our CTX cell therapy candidate for stroke disability in Japan under regulations that offer the potential for conditional marketing approval for cell therapies at an earlier stage of clinical development. In order to focus on the significant opportunity presented by our stroke disability programme and our expanded retinal disease programmes (see separate announcement issued this morning), we have decided to put the programme for critical limb ischaemia on hold for the time being. Patient dosing was recently completed in a Phase I safety study in this indication, with no significant adverse safety events reported post-administration of the CTX cells via intramuscular injections. Olav Hellebø, Chief Executive Officer of ReNeuron, said:
Regulatory Story Go to market news section View chart Print RNS Creo Medical Group PLC - CREO Creo CE Mark for microwave for Speedboat RS2 Released 07:00 24-Mar-2017 RNS Number : 4032A Creo Medical Group PLC 24 March 2017 Creo Medical Group plc ("Creo" or "the Company") CE Mark awarded to Speedboat RS2 for microwave energy Commercial plan on track Creo Medical Group plc (AIM: CREO) ("Creo" or "the Company"), a medical device company focused on the emerging field of surgical endoscopy, is pleased to announce that the Company's Speedboat RS2 has received CE Mark approval for microwave energy to add to the device's previously awarded CE Mark for radiofrequency. In clinical studies, the Speedboat RS2 has successfully demonstrated safety and efficacy of the application of microwave energy to coagulate bleeds in the colon in 30 patients and represents the first device to use microwave energy in combination with radiofrequency. The study publication has been accepted for Digestive Disease Week® (DDW), the world's largest medical meeting of physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Creo is developing the CROMA electrosurgery platform and the Speedboat RS2 is the first product in the instrument development pipeline. It harnesses the cut and coagulation capability of CROMA and enables the removal of large and flat pre-cancerous and cancerous lesions in the bowel which are typically referred for surgical removal in western practice; surgery which carries a 6% mortality rate at 30 days. Craig Gulliford, Chief Executive Officer of Creo Medical, said: "Our vision is to enable physicians to move the point of treatment from the operating theatre under general anaesthetic to a procedure under sedation in the endoscopy suite. Since the IPO, this is the first in a programme of necessary regulatory milestones expected for the CROMA platform and associated range of devices in the EU, the US and, working with our partners Pentax, the Asia Pacific region. We remain on track to initiate the soft launch of the Speedboat product later this year, in line with our strategy at IPO to translate this surgery sparing technology into routine clinical practice and expect this to be followed by the introduction of a range of devices for the therapeutic endoscopy market. Surgical endoscopy, a billion dollar plus market, is an emerging field and with the CROMA platform and range of endoscopic devices, we believe that we are well positioned to become a leader in this growing market." The information communicated in this announcement is inside information for the purposes of Article 7 of Market Abuse Regulation 596/2014 ("MAR"). Contacts Creo Medical: Cenkos: FTI Consulting: Roseanne Varner +44 (0)129 160 6005 roseanne.varner@creomedical.com Ivonne Cantu /
Is out . Why doesn't this site show it ? Do the premium accounts get them or just a lottery here ?
Moon was dead against that in PXS . He changes to benefit himself only, just that we have more mouths being added to this trough. The share prices indicate how good a job they are doing .....or not. Not you Alfie boy lol